{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:26Z","timestamp":1789981286239,"version":"4.0.1"},"reference-count":68,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.1080\/14656566.2026.2715709","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:00:21Z","timestamp":1786723221000},"page":"1251-1261","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The evolving landscape of phosphodiesterase inhibitors in atopic dermatitis management"],"prefix":"10.1080","volume":"27","author":[{"given":"Justyna","family":"Putek","sequence":"first","affiliation":[{"name":"Regional Specialist Hospital","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jaworek","sequence":"additional","affiliation":[{"name":"Jagiellonian University","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Wroclaw University of Science and Technology","place":["Wroclaw, Poland"]},{"name":"4th Military Hospital","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-29.6.587"},{"key":"e_1_3_4_4_1","first-page":"174","article-title":"Quality of life in patients with atopic dermatitis","volume":"104","author":"Koszor\u00fa K","year":"2019","unstructured":"Koszor\u00fa K, Borza J, Gul\u00e1csi L, et al. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174\u2013177.","journal-title":"Cutis"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae176"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104878"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14261"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01054-3"},{"key":"e_1_3_4_9_1","first-page":"18","article-title":"Structural insights: what makes some PDE4 inhibitors more effective in inflammatory dermatoses","volume":"18","author":"Issa NT","year":"2025","unstructured":"Issa NT, Wang J, Hanly A, et al. Structural insights: what makes some PDE4 inhibitors more effective in inflammatory dermatoses. J Clin Aesthet Dermatol. 2025;18(7):18\u201321.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000273"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13808"},{"issue":"5","key":"e_1_3_4_12_1","first-page":"364","article-title":"Therapeutic benefit of PDE4 inhibitors in inflammatory diseases","volume":"8","author":"Dastidar SG","year":"2007","unstructured":"Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8(5):364\u2013372.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201311083"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010091"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb03123.x"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152807780077318"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2021.54.3.233"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067925"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2016.11.026"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.812"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1995.17"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12462340"},{"key":"e_1_3_4_25_1","volume-title":"Eucrisa\u00ae (crisaborole) ointment, 2%, for topical use [package insert]","author":"Food and Drug Administration (FDA)","year":"2017","unstructured":"Food and Drug Administration (FDA). Eucrisa\u00ae (crisaborole) ointment, 2%, for topical use [package insert]. New York (NY): Anacor Pharmaceuticals\/Pfizer, Inc; 2017 Oct."},{"key":"e_1_3_4_26_1","unstructured":"Staquis (crisaborole) approval by European Medicines Agency. 2022 [cited 2026 Mar 1]. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/staquis"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212521"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.4.2604174"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/8755122519844507"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.11.056"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/17103568261431028"},{"issue":"12","key":"e_1_3_4_32_1","first-page":"1394","article-title":"A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis","volume":"14","author":"Stein Gold LF","year":"2015","unstructured":"Stein Gold LF, Spelman L, Spellman MC, et al. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14(12):1394\u20131399.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-025-00682-w"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00780-w"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0463-1"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.232819"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15840"},{"key":"e_1_3_4_39_1","unstructured":"FDA. ZORYVE\u00ae (roflumilast): prescribing information. FDA; 2024 Jul [cited 2026 Mar 1]. Available online https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215985s007lbl.pdf"},{"key":"e_1_3_4_40_1","unstructured":"FDA. ZORYVE\u00ae (roflumilast): prescribing information. FDA; 2023 Dec [cited 2026 Mar 1]. Available online https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217242s000lbl.pdf"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3121"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0418"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231169445"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15137"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00751-9"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01581-1"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.068"},{"key":"e_1_3_4_52_1","unstructured":"Judith Stewart Otezla FDA approval history. 2024 [cited 2026 Mar 1]. Available online: https:\/\/www.drugs.com"},{"key":"e_1_3_4_53_1","volume-title":"OTEZLA [package insert]","author":"Celgene Corporation","year":"2015","unstructured":"Celgene Corporation. OTEZLA [package insert]. Summit (NJ): Author; 2015."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.604745"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12428"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.043"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00703-1"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18906"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18818"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12377"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2016.1157257"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12534"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13231"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500378a"},{"issue":"11","key":"e_1_3_4_65_1","first-page":"1149","article-title":"AWD-12\u2013281 (inhaled) (elbion\/GlaxoSmithKline)","volume":"6","author":"Gutke HJ","year":"2005","unstructured":"Gutke HJ, Guse JH, Khobzaoui M, et al. AWD-12\u2013281 (inhaled) (elbion\/GlaxoSmithKline). Curr Opin Investig Drugs. 2005;6(11):1149\u20131158.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4990"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2020.1765633"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16126"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015064.pub2"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.034"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2715709","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2715709","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2715709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:11:34Z","timestamp":1789978294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2715709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,8,13]]}},"alternative-id":["10.1080\/14656566.2026.2715709"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2715709","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}